These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 16182195)

  • 1. Anticopper therapy against cancer and diseases of inflammation and fibrosis.
    Brewer GJ
    Drug Discov Today; 2005 Aug; 10(16):1103-9. PubMed ID: 16182195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risks of free copper in the body and the development of useful anticopper drugs.
    Brewer GJ
    Curr Opin Clin Nutr Metab Care; 2008 Nov; 11(6):727-32. PubMed ID: 18827576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases.
    Brewer GJ
    Metallomics; 2009; 1(3):199-206. PubMed ID: 21305118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of tetrathiomolybdate in treating fibrotic, inflammatory, and autoimmune diseases, including the non-obese diabetic mouse model.
    Brewer GJ; Dick R; Zeng C; Hou G
    J Inorg Biochem; 2006 May; 100(5-6):927-30. PubMed ID: 16321443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.
    Brewer GJ; Merajver SD
    Integr Cancer Ther; 2002 Dec; 1(4):327-37. PubMed ID: 14664727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of lowering copper levels with tetrathiomolybdate and zinc on mouse tumor and doxorubicin models.
    Hou G; Dick R; Zeng C; Brewer GJ
    Transl Res; 2006 Dec; 148(6):309-14. PubMed ID: 17162252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis.
    Brewer GJ; Dick R; Ullenbruch MR; Jin H; Phan SH
    J Inorg Biochem; 2004 Dec; 98(12):2160-7. PubMed ID: 15541506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation.
    Brewer GJ
    J Cell Mol Med; 2003; 7(1):11-20. PubMed ID: 12767257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement in dissolution of liver fibrosis in an animal model by tetrathiomolybdate.
    Hou G; Dick R; Brewer GJ
    Exp Biol Med (Maywood); 2009 Jun; 234(6):662-5. PubMed ID: 19307461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study.
    Brewer GJ; Dick RD; Grover DK; LeClaire V; Tseng M; Wicha M; Pienta K; Redman BG; Jahan T; Sondak VK; Strawderman M; LeCarpentier G; Merajver SD
    Clin Cancer Res; 2000 Jan; 6(1):1-10. PubMed ID: 10656425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The promise of copper lowering therapy with tetrathiomolybdate in the cure of cancer and in the treatment of inflammatory disease.
    Brewer GJ
    J Trace Elem Med Biol; 2014 Oct; 28(4):372-8. PubMed ID: 25194954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice.
    Brewer GJ; Ullenbruch MR; Dick R; Olivarez L; Phan SH
    J Lab Clin Med; 2003 Mar; 141(3):210-6. PubMed ID: 12624602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor and antiinflammatory effects of tetrathiotungstate in comparison with tetrathiomolybdate.
    Hou G; Dick R; Zeng C; Brewer GJ
    Transl Res; 2007 May; 149(5):260-4. PubMed ID: 17466925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine.
    Brewer GJ; Askari F; Dick RB; Sitterly J; Fink JK; Carlson M; Kluin KJ; Lorincz MT
    Transl Res; 2009 Aug; 154(2):70-7. PubMed ID: 19595438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pathogenesis and treatment of Wilson's disease].
    Nagy J; Vincze Z; Folhoffer A; Horváth A; Csák T; Zelkó R
    Acta Pharm Hung; 2003; 73(4):237-41. PubMed ID: 15279036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.
    Ping CC; Hassan Y; Aziz NA; Ghazali R; Awaisu A
    J Clin Pharm Ther; 2007 Feb; 32(1):101-7. PubMed ID: 17286794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease.
    Brewer GJ; Askari F; Lorincz MT; Carlson M; Schilsky M; Kluin KJ; Hedera P; Moretti P; Fink JK; Tankanow R; Dick RB; Sitterly J
    Arch Neurol; 2006 Apr; 63(4):521-7. PubMed ID: 16606763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of tetrathiomolybdate in a mouse model of multiple sclerosis.
    Hou G; Abrams GD; Dick R; Brewer GJ
    Transl Res; 2008 Nov; 152(5):239-44. PubMed ID: 19010295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Wilson's disease with zinc. XVII: treatment during pregnancy.
    Brewer GJ; Johnson VD; Dick RD; Hedera P; Fink JK; Kluin KJ
    Hepatology; 2000 Feb; 31(2):364-70. PubMed ID: 10655259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease.
    Brewer GJ
    Exp Biol Med (Maywood); 2001 Jul; 226(7):665-73. PubMed ID: 11444102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.